Table 1.
Study period | ||||||
---|---|---|---|---|---|---|
Enrolment | Allocation | Post-allocation | Close-out | |||
Time points* | −T1 | T0 | T1 | T2 | T3 | Tx |
Enrolment: | ||||||
Eligibility screen | X | |||||
Informed consent | X | |||||
Allocation | X | |||||
Intervention: | ||||||
Bone biopsy and ulcer bed biopsy | X | |||||
Assessments: | ||||||
Baseline variables: | ||||||
Demographic data | X | |||||
Plain X-ray and/or MRI and/or FDG-PET | X | |||||
Foot temperatures | X | X | X | X | ||
Peripheral arterial status | X | X | X | X | ||
Standard laboratory tests | X | X | X | X | ||
Microbiology bone/ulcer bed biopsy | X | |||||
Outcome variables: | ||||||
Remission of osteomyelitis | X | |||||
Time to remission | X | X | X | |||
Signs of inflammation | X | X | X | X | ||
Ulceration at the primary location of infection | X | X | X | |||
Microbiological and molecular profiles of bone and ulcer bed cultures | X | |||||
Occurrence of any surgical amputation | X | X | X | |||
Total antibacterial therapy duration | X | X | X | |||
Infection-free survival days | X | X | X | |||
Quality of life | X | X | X | |||
Survival | X | X | X | |||
Adverse events | X | X | X |
*Specification of time points: